<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1773</number>
    <updateDate>2023-01-15T08:03:18Z</updateDate>
    <updateDateIncludingText>2023-01-15T08:03:18Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2003-10-22</introducedDate>
    <congress>108</congress>
    <committees>
      <item>
        <systemCode>ssfi00</systemCode>
        <name>Finance Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2003-10-22T17:03:15Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Biotechnology Future Investment Expansion Act of 2003</title>
        <congress>108</congress>
        <number>2968</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2003-07-25</actionDate>
          <text>Referred to the House Committee on Ways and Means.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2003-10-22</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2003-10-22</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>S000059</bioguideId>
        <fullName>Sen. Santorum, Rick [R-PA]</fullName>
        <firstName>RICK</firstName>
        <lastName>SANTORUM</lastName>
        <party>R</party>
        <state>PA</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C000174</bioguideId>
        <fullName>Sen. Carper, Thomas R. [D-DE]</fullName>
        <firstName>Thomas</firstName>
        <lastName>Carper</lastName>
        <party>D</party>
        <state>DE</state>
        <middleName>R.</middleName>
        <sponsorshipDate>2003-10-22</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>H000338</bioguideId>
        <fullName>Sen. Hatch, Orrin G. [R-UT]</fullName>
        <firstName>ORRIN</firstName>
        <lastName>HATCH</lastName>
        <party>R</party>
        <state>UT</state>
        <middleName>GRANT</middleName>
        <sponsorshipDate>2004-05-03</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>A000121</bioguideId>
        <fullName>Sen. Allen, George [R-VA]</fullName>
        <firstName>GEORGE</firstName>
        <lastName>ALLEN</lastName>
        <party>R</party>
        <state>VA</state>
        <middleName>F.</middleName>
        <sponsorshipDate>2004-09-07</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Taxation</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Accounting</name>
        </item>
        <item>
          <name>Capital gains tax</name>
        </item>
        <item>
          <name>Clinical trials</name>
        </item>
        <item>
          <name>Commerce</name>
        </item>
        <item>
          <name>Corporate debt</name>
        </item>
        <item>
          <name>Corporate finance</name>
        </item>
        <item>
          <name>Corporate reorganizations</name>
        </item>
        <item>
          <name>Corporation taxes</name>
        </item>
        <item>
          <name>Drug industry</name>
        </item>
        <item>
          <name>Finance and Financial Sector</name>
        </item>
        <item>
          <name>Health</name>
        </item>
        <item>
          <name>Income tax</name>
        </item>
        <item>
          <name>Investments</name>
        </item>
        <item>
          <name>Losses</name>
        </item>
        <item>
          <name>Pharmaceutical research</name>
        </item>
        <item>
          <name>Science, Technology, Communications</name>
        </item>
        <item>
          <name>Tax credits</name>
        </item>
        <item>
          <name>Tax exclusion</name>
        </item>
        <item>
          <name>Tax incentives</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Taxation</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2003-10-22</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2003-11-05T18:22:56Z</updateDate>
        <text><![CDATA[ <p>Biotechnology Future Investment Expansion Act of 2003 - Amends the Internal Revenue Code to provide that in the case of a biomedical research corporation, any owner shift involving a five-percent shareholder which occurs as the result of a qualified investment during the testing period shall be treated as occurring before the testing period. (Thus not counting toward net operating loss and tax credit carryover limitations.)</p> <p>Defines: (1) &quot;biomedical research corporation&quot; as a domestic corporation not in bankruptcy which has a drug or biologic in certain clinical trials; and (2) &quot;qualified investment&quot; as a stock acquisition in a biomedical research corporation acquired in cash at its original issue.</p> <p>Requires a biomedical research corporation to meet a five-year expenditure test with respect to any qualified investment.</p>]]></text>
      </summary>
    </summaries>
    <title>Biotechnology Future Investment Expansion Act of 2003</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Biotechnology Future Investment Expansion Act of 2003</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to permit biomedical research corporations to engage in certain equity financings without incurring limitations on net operating loss carryforwards and certain built-in losses, and for other purposes.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Biotechnology Future Investment Expansion Act of 2003</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2003-10-22T04:00:00Z</date>
        <formats/>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2003-10-22</actionDate>
      <text>Read twice and referred to the Committee on Finance.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
